首页> 外文期刊>Annals of allergy, asthma, and immunology >Effect of mite allergen immunotherapy on the altered phenotype of dendritic cells in allergic asthmatic children
【24h】

Effect of mite allergen immunotherapy on the altered phenotype of dendritic cells in allergic asthmatic children

机译:螨过敏原免疫疗法对过敏性哮喘儿童树突状细胞表型改变的影响

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Allergic asthma is a TH2 inflammatory disease. Dendritic cells (DCs) play key roles in the TH1/TH2 balance. Allergen specific immunotherapy (SIT) has the potential to modify the course of allergy because the ratio of TH1 to TH2 cytokines produced is increased after SIT. Objective: To determine how SIT affects DCs in children and to define novel parameters of this treatment. Methods: We investigated the changes of phenotypic and functional variations of monocyte-derived DCs from allergic asthmatic children undergoing complete mite SIT. Peripheral blood monocytes from SIT allergic asthmatic children, allergic asthmatic controls, and healthy controls were cultured with granulocyte- macrophage colony-stimulating factor and interleukin 4 and then stimulated with Dermatophagoides pteronyssinus (Der p) allergen or lipopolysaccharide (LPS). The expressions of surface molecules on monocyte-derived DCs were assessed by flow cytometry. Cytokine production by cultured monocyte-derived DCs was determined by enzyme-linked immunosorbent assay. Results: After LPS stimulation, monocyte-derived DCs of the allergic asthmatic group had a higher CD86 and lower HLA-DR expression than the healthy controls. In SIT patients, the expression was similar to that of the healthy controls. After Der p stimulation monocyte-derived DCs of the allergic asthmatic patients displayed lower Toll-like receptor 4 (TLR4), whereas again in SIT patients the expression was similar to that of healthy controls. Conclusion: These findings indicate that SIT normalizes the expression of CD86, HLA-DR, and TLR4 on DCs. Moreover, CD86, HLA-DR, and TLR4 may be useful parameters for monitoring SIT. Decreased TLR4 expression in allergic asthmatic patients might be compensated by TLR4 agonists, with the potential of amplifying the effects of SIT. ? 2013 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
机译:背景:过敏性哮喘是一种TH2炎症性疾病。树突状细胞(DC)在TH1 / TH2平衡中起关键作用。过敏原特异性免疫疗法(SIT)可能会改变过敏的进程,因为SIT后产生的TH1与TH2细胞因子之比增加。目的:确定SIT如何影响儿童DC,并定义这种治疗的新参数。方法:我们调查了接受完全螨SIT的过敏性哮喘儿童单核细胞DC的表型和功能变化。用粒细胞巨噬细胞集落刺激因子和白介素4培养来自SIT过敏性哮喘儿童,过敏性哮喘对照和健康对照的外周血单核细胞,然后用Dermatophagoides pteronyssinus(Der p)过敏原或脂多糖(LPS)刺激。通过流式细胞术评估表面分子在单核细胞衍生的DC上的表达。通过酶联免疫吸附测定来确定培养的单核细胞衍生的DC产生的细胞因子。结果:LPS刺激后,过敏性哮喘组的单核细胞衍生DC具有比健康对照组更高的CD86和更低的HLA-DR表达。在SIT患者中,该表达与健康对照组的表达相似。在Der p刺激后,过敏性哮喘患者的单核细胞衍生DC表现出较低的Toll样受体4(TLR4),而在SIT患者中,其表达与健康对照相似。结论:这些发现表明SIT使DC上CD86,HLA-DR和TLR4的表达正常化。此外,CD86,HLA-DR和TLR4可能是用于监视SIT的有用参数。变态反应性哮喘患者中TLR4表达的降低可能被TLR4激动剂所补偿,并具有扩大SIT作用的潜力。 ? 2013年美国过敏,哮喘与免疫学院。由Elsevier Inc.出版。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号